| __timestamp | Neurocrine Biosciences, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 179279000 |
| Thursday, January 1, 2015 | 33800000 | 186359000 |
| Friday, January 1, 2016 | 35900000 | 171785000 |
| Sunday, January 1, 2017 | 1254000 | 208136000 |
| Monday, January 1, 2018 | 4889000 | 198405000 |
| Tuesday, January 1, 2019 | 7400000 | 224169000 |
| Wednesday, January 1, 2020 | 10100000 | 245044000 |
| Friday, January 1, 2021 | 14300000 | 252314000 |
| Saturday, January 1, 2022 | 23200000 | 268225000 |
| Sunday, January 1, 2023 | 39700000 | 304629000 |
| Monday, January 1, 2024 | 34000000 | 324203000 |
Data in motion
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. Neurocrine Biosciences, Inc. and Taro Pharmaceutical Industries Ltd. have shown contrasting trends in their cost of revenue from 2014 to 2023. Neurocrine Biosciences, Inc. started with a modest cost of revenue, which surged by over 175% from 2014 to 2023, peaking at nearly $40 million. This reflects their aggressive expansion and investment in innovative therapies. In contrast, Taro Pharmaceutical Industries Ltd. maintained a more stable trajectory, with costs increasing by approximately 70% over the same period, reaching over $300 million in 2023. This stability underscores Taro's focus on optimizing production efficiencies. Notably, 2024 data for Neurocrine is missing, hinting at potential strategic shifts. These trends offer a window into the strategic priorities and market positioning of these industry leaders.
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: AstraZeneca PLC vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Pfizer Inc. and Taro Pharmaceutical Industries Ltd.'s Expenses
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Xenon Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.